At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine on the Pharmacokinetics of Atazanavir in HIV-Infected Subjects Receiving Atazanavir With Ritonavir and Tenofovir
In Brief
A Phase 4 clinical trial evaluating Atazanavir, Ritonavir, and 3 other interventions for HIV. Completed, enrolled 25 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the effects of famotidine, given twice daily, on atazanavir administered with ritonavir and tenofovir in HIV-infected participants.
Study Details
Timeline
Interventions
Capsule, oral, 300 mg, once daily, 10 days
Capsule, oral, 400 mg, once daily, 7 days
Capsule, oral, 100 mg, once daily, 10 days
Capsule, oral, 100 mg, once daily, 7 days
Capsule, oral, 300 mg, once daily, 10 days
Capsule, oral, 300 mg, once daily, 7 days
Oral, 10 days
Oral, 7 days
Tablet, oral, 20 mg, twice daily, 7 days
Tablet, oral, 40 mg, twice daily, 7 days